ARCHIVES

Afinitor Increases Overall Survival To 3.5 Years in Phase III Trial

This article is from The Cancer Letter archive.

Vol. 37 No. 9 | September 26, 2014

Download PDF Visit The Full Archive

Related Articles

Federal Regs Prohibit RFP Budget Releases

February 21, 1975

NCI-Approved Clinical Trials

April 26, 2002

Unwanted Distinction: MSKCC Bars Zaltrap From Formulary, Triggering Debate Over Drug Pricing

November 1, 2012

In Brief: NCAB To Meet Jan. 15-17; UCLA To Compete For Clinical Neutron Therapy Contract

January 5, 1979

RFAs For Extramural Construction, Mouse Facility Available

March 2, 1990

Recurrent Multiple Myeloma Responds To Revimid In Phase II, Side Effects Tolerable

January 31, 2003